Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more.

Del Mistro A, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, Rizzolo R, Frayle H, Trevisan M, Sani C, Burroni E, Giorgi Rossi P, Cuzick J, Ronco G; New Technologies for Cervical CancerWorking Group.

Int J Cancer. 2018 Jul 15;143(2):333-342. doi: 10.1002/ijc.31326. Epub 2018 Mar 9.

2.

The evolution of the epidemiological landscape of head and neck cancer in Italy: Is there evidence for an increase in the incidence of potentially HPV-related carcinomas?

Boscolo-Rizzo P, Zorzi M, Del Mistro A, Da Mosto MC, Tirelli G, Buzzoni C, Rugge M, Polesel J, Guzzinati S; AIRTUM Working Group.

PLoS One. 2018 Feb 7;13(2):e0192621. doi: 10.1371/journal.pone.0192621. eCollection 2018.

3.

Low prevalence of HPV-driven head and neck squamous cell carcinoma in North-East Italy.

Baboci L, Holzinger D, Boscolo-Rizzo P, Tirelli G, Spinato R, Lupato V, Fuson R, Schmitt M, Michel A, Halec G, Da Mosto MC, Pawlita M, Del Mistro A.

Papillomavirus Res. 2016 Dec;2:133-140. doi: 10.1016/j.pvr.2016.07.002. Epub 2016 Jul 16.

4.

Multicenter research into the quality of life of patients with advanced oropharyngeal carcinoma with long-term survival associated with human papilloma virus.

Spinato G, Stellin M, Azzarello G, Bonazza D, Zanconati F, Politi D, Cocuzza S, Di Mauro P, Ausoni S, Tonoli G, Costantini G, Maiolino L, Spinato R, Da Mosto MC, Baboci L, Del Mistro A, Serra A, Tirelli G.

Oncol Lett. 2017 Jul;14(1):185-193. doi: 10.3892/ol.2017.6152. Epub 2017 May 10.

5.

Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.

Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, Pittaluga S, Bamford RN, Nakagawa M, Ouyang ST, Epstein AL, Kadin ME, Del Mistro A, Woessner R, Jaffe ES, Waldmann TA.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3975-3980. doi: 10.1073/pnas.1700682114. Epub 2017 Mar 29.

6.

Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma.

Holzinger D, Wichmann G, Baboci L, Michel A, Höfler D, Wiesenfarth M, Schroeder L, Boscolo-Rizzo P, Herold-Mende C, Dyckhoff G, Boehm A, Del Mistro A, Bosch FX, Dietz A, Pawlita M, Waterboer T.

Int J Cancer. 2017 Jun 15;140(12):2748-2757. doi: 10.1002/ijc.30697. Epub 2017 Apr 4.

7.

Methylation analysis and HPV genotyping of self-collected cervical samples from women not responding to screening invitation and review of the literature.

Del Mistro A, Frayle H, Rizzi M, Fantin G, Ferro A, Angeletti PM, Giorgi Rossi P, Altobelli E.

PLoS One. 2017 Mar 6;12(3):e0172226. doi: 10.1371/journal.pone.0172226. eCollection 2017.

8.

A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study.

Zorzi M, Frayle H, Rizzi M, Fedato C, Rugge M, Penon MG, Bertazzo A, Callegaro S, Campagnolo M, Ortu F, Del Mistro A; and the Veneto HPV-screening Working Group.

BJOG. 2017 Sep;124(10):1585-1593. doi: 10.1111/1471-0528.14575. Epub 2017 Apr 12.

9.

Prevalence and Determinants of Oral Human Papillomavirus Infection in 500 Young Adults from Italy.

Lupato V, Holzinger D, Höfler D, Menegaldo A, Giorgi Rossi P, Del Mistro A, Da Mosto MC, Pawlita M, Boscolo-Rizzo P.

PLoS One. 2017 Jan 19;12(1):e0170091. doi: 10.1371/journal.pone.0170091. eCollection 2017.

10.

Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.

Giorgi Rossi P, Bisanzi S, Allia E, Mongia A, Carozzi F, Gillio-Tos A, De Marco L, Ronco G, Gustinucci D, Del Mistro A, Frayle H, Iossa A, Fantacci G, Pompeo G, Cesarini E, Bulletti S, Passamonti B, Rizzi M, Penon MG, Barca A, Benevolo M.

J Clin Microbiol. 2017 Apr;55(4):1056-1065. doi: 10.1128/JCM.01794-16. Epub 2017 Jan 18.

11.

Efficacy of self-sampling in promoting participation to cervical cancer screening also in subsequent round.

Del Mistro A, Frayle H, Ferro A, Fantin G, Altobelli E, Giorgi Rossi P.

Prev Med Rep. 2016 Dec 23;5:166-168. doi: 10.1016/j.pmedr.2016.12.017. eCollection 2017 Mar.

12.

Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms.

Ronco G, Zappa M, Franceschi S, Tunesi S, Caprioglio A, Confortini M, Del Mistro A, Carozzi F, Segnan N, Zorzi M, Giorgi-Rossi P; Italian HPV Survey Working Group.

Eur J Cancer. 2016 Nov;68:148-155. doi: 10.1016/j.ejca.2016.09.008. Epub 2016 Oct 15.

13.

Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.

Boscolo-Rizzo P, Da Mosto MC, Rampazzo E, Giunco S, Del Mistro A, Menegaldo A, Baboci L, Mantovani M, Tirelli G, De Rossi A.

Cancer Metastasis Rev. 2016 Sep;35(3):457-74. doi: 10.1007/s10555-016-9633-1. Review.

14.

GISCi: an opportunity for more consideration and visibility for young researchers.

Carozzi FM, Giorgi Rossi P, Matucci M, Iossa A, Del Mistro A, Maina G, Venturino E, Taddei GL, Giaimo MD.

Epidemiol Prev. 2016 May-Aug;40(3-4):150. doi: 10.19191/EP16.3-4.AD01.075. No abstract available.

15.

Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.

Kostareli E, Hielscher T, Zucknick M, Baboci L, Wichmann G, Holzinger D, Mücke O, Pawlita M, Del Mistro A, Boscolo-Rizzo P, Da Mosto MC, Tirelli G, Plinkert P, Dietz A, Plass C, Weichenhan D, Hess J.

Epigenetics. 2016;11(1):61-73. doi: 10.1080/15592294.2015.1137414. Epub 2016 Jan 19.

16.

HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance.

Carozzi FM, Del Mistro A, Cuschieri K, Frayle H, Sani C, Burroni E.

J Clin Virol. 2016 Mar;76 Suppl 1:S22-S28. doi: 10.1016/j.jcv.2015.10.025. Epub 2015 Nov 10. Review.

PMID:
26669512
17.

hr-HPV testing in the management of women with ASC-US+ and in the follow-up of women with cytological abnormalities and negative colposcopy. Recommendations of the Italian group for cervical cancer screening (GISCi).

Carozzi FM, Iossa A, Scalisi A, Sideri M, Andersson KL, Confortini M, Del Mistro A, Maina G, Ronco G, Raggi P, Schiboni ML, Zappa M, Giorgi Rossi P.

Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):84-90.

18.

A first survey of HPV-based screening in routine cervical cancer screening in Italy.

Ronco G, Giorgi Rossi P, Giubilato P, Del Mistro A, Zappa M, Carozzi F; HPV screening survey group.

Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):77-83.

19.

Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion.

Rossi PG, Ronco G, Dillner J, Elfström KM, Snijders PJ, Arbyn M, Berkhof J, Carozzi F, Del Mistro A, De Sanjosè S, Bosch X, Petry KU, Poljak M, Naldoni C, Meijer CJ; Comparing Health Services Interventions for the Prevention of HPV-Related Cancer Consortium; New Technologies for Cervical Cancer Group.

Cancer Cytopathol. 2016 Jan;124(1):66-7. doi: 10.1002/cncy.21622. Epub 2015 Sep 10. No abstract available.

20.

SERS analysis of serum for detection of early and locally advanced breast cancer.

Cervo S, Mansutti E, Del Mistro G, Spizzo R, Colombatti A, Steffan A, Sergo V, Bonifacio A.

Anal Bioanal Chem. 2015 Sep;407(24):7503-9. doi: 10.1007/s00216-015-8923-8. Epub 2015 Aug 9.

PMID:
26255294
21.

Long-Term Clinical Outcome after Treatment for High-Grade Cervical Lesions: A Retrospective Monoinstitutional Cohort Study.

Del Mistro A, Matteucci M, Insacco EA, Onnis G, Da Re F, Baboci L, Zorzi M, Minucci D.

Biomed Res Int. 2015;2015:984528. doi: 10.1155/2015/984528. Epub 2015 Jun 9.

22.

HPV Genotyping in the Prevention of Cervical Cancer-How and When Can It Be a Useful Marker?

Del Mistro A.

Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1302-3. doi: 10.1158/1055-9965.EPI-15-0591. Epub 2015 Jun 18. No abstract available.

23.

Surface-enhanced Raman spectroscopy of urine for prostate cancer detection: a preliminary study.

Del Mistro G, Cervo S, Mansutti E, Spizzo R, Colombatti A, Belmonte P, Zucconelli R, Steffan A, Sergo V, Bonifacio A.

Anal Bioanal Chem. 2015 May;407(12):3271-5. doi: 10.1007/s00216-015-8610-9. Epub 2015 Mar 20.

PMID:
25791298
24.

Telomere shortening in mucosa surrounding the tumor: biosensor of field cancerization and prognostic marker of mucosal failure in head and neck squamous cell carcinoma.

Boscolo-Rizzo P, Rampazzo E, Perissinotto E, Piano MA, Giunco S, Baboci L, Spinato G, Spinato R, Tirelli G, Da Mosto MC, Del Mistro A, De Rossi A.

Oral Oncol. 2015 May;51(5):500-7. doi: 10.1016/j.oraloncology.2015.02.100. Epub 2015 Mar 11.

PMID:
25771075
25.

Self-sampling to increase participation in cervical cancer screening: an RCT comparing home mailing, distribution in pharmacies, and recall letter.

Giorgi Rossi P, Fortunato C, Barbarino P, Boveri S, Caroli S, Del Mistro A, Ferro A, Giammaria C, Manfredi M, Moretto T, Pasquini A, Sideri M, Tufi MC, Cogo C, Altobelli E; HPV Self-sampling Italian Working Group.

Br J Cancer. 2015 Feb 17;112(4):667-75. doi: 10.1038/bjc.2015.11. Epub 2015 Jan 29.

26.

The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials.

Veldhuijzen NJ, Berkhof J, Gillio-Tos A, De Marco L, Carozzi F, Del Mistro A, Snijders PJ, Meijer CJ, Ronco G.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):111-8. doi: 10.1158/1055-9965.EPI-14-0628. Epub 2014 Oct 9.

27.

Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.

Carozzi F, De Marco L, Gillio-Tos A, Del Mistro A, Girlando S, Baboci L, Trevisan M, Burroni E, Grasso S, Giorgi Rossi P, Ronco G; NTCC Working Group.

J Clin Virol. 2014 Jul;60(3):257-63. doi: 10.1016/j.jcv.2014.04.009. Epub 2014 Apr 18.

PMID:
24815381
28.

Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.

Del Mistro A, Frayle H, Ferro A, Callegaro S, Del Sole A, Stomeo A, Cirillo E, Fedato C, Pagni S, Barzon L, Zorzi M; Veneto HPV-screening Working Group.

J Med Screen. 2014 Mar;21(1):30-7. doi: 10.1177/0969141314522219. Epub 2014 Jan 31.

PMID:
24488593
29.

Type-specific human papillomavirus biological features: validated model-based estimates.

Baussano I, Elfström KM, Lazzarato F, Gillio-Tos A, De Marco L, Carozzi F, Del Mistro A, Dillner J, Franceschi S, Ronco G.

PLoS One. 2013 Nov 29;8(11):e81171. doi: 10.1371/journal.pone.0081171. eCollection 2013.

30.

Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma.

Baboci L, Boscolo-Rizzo P, Holzinger D, Bertorelle R, Biasini L, Michel A, Schmitt M, Spinato G, Bussani R, Alemany L, Tirelli G, Da Mosto MC, Del Mistro A, Pawlita M.

Virol J. 2013 Nov 12;10:334. doi: 10.1186/1743-422X-10-334.

31.

New insights into human papillomavirus-associated head and neck squamous cell carcinoma.

Boscolo-Rizzo P, Del Mistro A, Bussu F, Lupato V, Baboci L, Almadori G, DA Mosto MC, Paludetti G.

Acta Otorhinolaryngol Ital. 2013 Apr;33(2):77-87. Review.

32.

Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.

Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, Frayle-Salamanca H, Giorgi Rossi P, Pierotti P, Ronco G; New Technologies for Cervical Cancer Screening Working Group.

J Clin Microbiol. 2013 Sep;51(9):2901-7. doi: 10.1128/JCM.01047-13. Epub 2013 Jun 26.

33.

Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.

Zorzi M, Del Mistro A, Farruggio A, de'Bartolomeis L, Frayle-Salamanca H, Baboci L, Bertazzo A, Cocco P, Fedato C, Gennaro M, Marchi N, Penon MG, Cogo C, Ferro A.

BJOG. 2013 Sep;120(10):1260-7; discussion 1267-8. doi: 10.1111/1471-0528.12272. Epub 2013 Jun 21.

34.

Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial.

Baussano I, Franceschi S, Gillio-Tos A, Carozzi F, Confortini M, Dalla Palma P, De Lillo M, Del Mistro A, De Marco L, Naldoni C, Pierotti P, Schincaglia P, Segnan N, Zorzi M, Giorgi-Rossi P, Ronco G.

BMC Infect Dis. 2013 May 24;13:238. doi: 10.1186/1471-2334-13-238.

35.

Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.

Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, Girlando S, Rosso S, Naldoni C, Dalla Palma P, Zorzi M, Giorgi-Rossi P, Segnan N, Cuzick J, Ronco G; NTCC working group.

Lancet Oncol. 2013 Feb;14(2):168-76. doi: 10.1016/S1470-2045(12)70529-6. Epub 2012 Dec 21.

PMID:
23261355
36.

HPV16 genetic variation and the development of cervical cancer worldwide.

Cornet I, Gheit T, Iannacone MR, Vignat J, Sylla BS, Del Mistro A, Franceschi S, Tommasino M, Clifford GM.

Br J Cancer. 2013 Jan 15;108(1):240-4. doi: 10.1038/bjc.2012.508. Epub 2012 Nov 20.

37.

Oral human papillomavirus and human herpesvirus-8 infections among human immunodeficiency virus type 1-infected men and women in Italy.

Del Mistro A, Baboci L, Frayle-Salamanca H, Trevisan R, Bergamo E, Lignitto L, Sasset L, Cecchetto MG, Cattelan AM, Calabró ML.

Sex Transm Dis. 2012 Nov;39(11):894-8. doi: 10.1097/OLQ.0b013e31826ef2da.

PMID:
23064540
38.

HPV testing is an efficient management choice for women with inadequate liquid-based cytology in cervical cancer screening.

Giorgi Rossi P, Carozzi F, Collina G, Confortini M, Dalla Palma P, De Lillo M, Del Mistro A, Ghiringhello B, Gillio-Tos A, Maioli P, Pellegrini A, Schiboni ML, Segnan N, Zaffina LM, Zorzi M, Ronco G; NTCC Working Group.

Am J Clin Pathol. 2012 Jul;138(1):65-71. doi: 10.1309/AJCP6J2OEFOYTRFD.

PMID:
22706859
39.

Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study.

Carozzi F, Ronco G, Gillio-Tos A, De Marco L, Del Mistro A, Girlando S, Franceschi S, Plummer M, Vaccarella S; New Technologies for Cervical Cancer screening (NTCC) Working Group.

Eur J Cancer. 2012 Jul;48(11):1633-7. doi: 10.1016/j.ejca.2011.10.010. Epub 2011 Nov 14.

PMID:
22088483
40.

Triage of women with atypical squamous cells of undetermined significance (ASC-US): results of an Italian multicentric study.

Del Mistro A, Frayle-Salamanca H, Trevisan R, Matteucci M, Pinarello A, Zambenedetti P, Buoso R, Fantin GP, Zorzi M, Minucci D.

Gynecol Oncol. 2010 Apr;117(1):77-81. doi: 10.1016/j.ygyno.2010.01.003. Epub 2010 Feb 8.

PMID:
20116836
41.

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J; New Technologies for Cervical Cancer screening (NTCC) Working Group.

Lancet Oncol. 2010 Mar;11(3):249-57. doi: 10.1016/S1470-2045(09)70360-2. Epub 2010 Jan 18.

PMID:
20089449
42.

Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY).

Oeth P, del Mistro G, Marnellos G, Shi T, van den Boom D.

Methods Mol Biol. 2009;578:307-43. doi: 10.1007/978-1-60327-411-1_20.

PMID:
19768603
43.

TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies.

Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, Ciotti M, Das BR, Del Mistro A, Dybikowska A, Giuliano AR, Gudleviciene Z, Gyllensten U, Haws AL, Helland A, Herrington CS, Hildesheim A, Humbey O, Jee SH, Kim JW, Madeleine MM, Menczer J, Ngan HY, Nishikawa A, Niwa Y, Pegoraro R, Pillai MR, Ranzani G, Rezza G, Rosenthal AN, Roychoudhury S, Saranath D, Schmitt VM, Sengupta S, Settheetham-Ishida W, Shirasawa H, Snijders PJ, Stoler MH, Suárez-Rincón AE, Szarka K, Tachezy R, Ueda M, van der Zee AG, von Knebel Doeberitz M, Wu MT, Yamashita T, Zehbe I, Blettner M.

Lancet Oncol. 2009 Aug;10(8):772-84. doi: 10.1016/S1470-2045(09)70187-1. Epub 2009 Jul 20.

PMID:
19625214
44.

Extensive anal condylomatosis: prognosis in relation to viral and host factors.

Sarzo G, Del Mistro A, Finco C, Frayle-Salamanca H, Marino F, Franzetti M, Ferrara R, Mistrangelo M, Savastano S, Vecchiato M, Merigliano S.

Colorectal Dis. 2010 Jul;12(7 Online):e128-34. doi: 10.1111/j.1463-1318.2009.01902.x. Epub 2009 Apr 13. Erratum in: Colorectal Dis. 2010 Oct;12(10):1072. Mistro, A [corrected to Del Mistro, A].

PMID:
19508521
45.

Subacute onset of deafness and vertigo in a patient with leptomeningeal metastasis from ovarian cancer.

Vitaliani R, Spinazzi M, Del Mistro AR, Manara R, Tavolato B, Bonifati DM.

Neurol Sci. 2009 Feb;30(1):65-7. doi: 10.1007/s10072-008-0006-6. Epub 2009 Jan 16.

PMID:
19148572
46.

HPV-16 E6 L83V variant in squamous cell carcinomas of the upper aerodigestive tract.

Boscolo-Rizzo P, Da Mosto MC, Fuson R, Frayle-Salamanca H, Trevisan R, Del Mistro A.

J Cancer Res Clin Oncol. 2009 Apr;135(4):559-66. doi: 10.1007/s00432-008-0490-3. Epub 2008 Oct 8.

PMID:
18841393
47.

Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.

Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, Giorgi-Rossi P, Pontenani G, Rosso S, Sani C, Sintoni C, Segnan N, Zorzi M, Cuzick J, Rizzolo R, Ronco G; New Technologies for Cervival Cancer Screening (NTCC) Working Group.

Lancet Oncol. 2008 Oct;9(10):937-45. doi: 10.1016/S1470-2045(08)70208-0. Epub 2008 Sep 8.

PMID:
18783988
48.

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N; New Technologies for Cervical Cancer Screening Working Group.

J Natl Cancer Inst. 2008 Apr 2;100(7):492-501. doi: 10.1093/jnci/djn065. Epub 2008 Mar 25.

PMID:
18364502
49.

ASC-US diagnosis and triage.

Del Mistro A.

Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S2-4. Epub 2007 Aug 28. No abstract available.

PMID:
17727939
50.

HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology.

Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, Dalla Palma P, Del Mistro A, Gillio-Tos A, Giubilato P, Naldoni C, Polla E, Iossa A, Zorzi M, Confortini M, Giorgi-Rossi P; NTCC working group.

Eur J Cancer. 2007 Feb;43(3):476-80. Epub 2007 Jan 12.

PMID:
17223540

Supplemental Content

Loading ...
Support Center